Asset Portfolio
Asset Portfolio
Asset Portfolio
Small Molecule
Small Molecule
Asset #
Therapeutic Area
Target
Stage of Developement
SG1063
Oncology
FAK/SRC
IND Ready
SG1064
Diabetes / Obesity
GLP1
Oran IND Ready
SG1066
Oncology
KRAS G12D
Phase 1
SG1067
Oncology
Brain Penetrable BTK
Phase 2
SG1068
Oncology
Pan-KRAS
Preclinical
SG1069
Pain
Nav1.8
Phase 1
SG1070
Oncology
BTK/IRAK4 Degrader
Preclinical
SG1071
Oncology
TYK Degrader
Preclinical
SG1072
Oncology
Microtubule Stabilizing Agent
Launched in China
SG1073
Oncology
Microtubule Stabilizing Agent
Phase 3 in China
Asset #
Therapeutic Area
Target
Stage of Developement
SG1063
Oncology
FAK/SRC
IND Ready
SG1064
Diabetes / Obesity
GLP1
Oran IND Ready
SG1066
Oncology
KRAS G12D
Phase 1
SG1067
Oncology
Brain Penetrable BTK
Phase 2
SG1068
Oncology
Pan-KRAS
Preclinical
SG1069
Pain
Nav1.8
Phase 1
SG1070
Oncology
BTK/IRAK4 Degrader
Preclinical
SG1071
Oncology
TYK Degrader
Preclinical
SG1072
Oncology
Microtubule Stabilizing Agent
Launched in China
SG1073
Oncology
Microtubule Stabilizing Agent
Phase 3 in China
Asset #
Therapeutic Area
Target
Stage of Developement
SG1063
Oncology
FAK/SRC
IND Ready
SG1064
Diabetes / Obesity
GLP1
Oran IND Ready
SG1066
Oncology
KRAS G12D
Phase 1
SG1067
Oncology
Brain Penetrable BTK
Phase 2
SG1068
Oncology
Pan-KRAS
Preclinical
SG1069
Pain
Nav1.8
Phase 1
SG1070
Oncology
BTK/IRAK4 Degrader
Preclinical
SG1071
Oncology
TYK Degrader
Preclinical
SG1072
Oncology
Microtubule Stabilizing Agent
Launched in China
SG1073
Oncology
Microtubule Stabilizing Agent
Phase 3 in China
Large Molecule
Large Molecule
Asset #
Therapeutic Area
Target
Stage of Developement
SG2022
Immunology
TSLP Nanobody inhale
Phase 1 in China
SG2023
Immunology
IL-4Rα Nanobody inhale
Phase 1 in China
SG2026
Oncology
GPRC5D binder
Preclinical
SG2037
Oncology/Immunology
CD20/CD3
Phase 1 in China
SG2040
Diabetes/Obesity
GLP1/GIP
Phase 1 in China
SG2041
Oncology/Immunology
CD38/CD3
Preclinical
SG2043
Oncology/Immunology
BCMA/CD3
Phase 1 in China
SG2044
Oncology/Immunology
CD19/CD3
Phase 1 in China
SG2045
Immunology
BCMA/CD19/CD3
Preclinical
SG2046
RA, Osteoporosis
TNFa/RANKL
IND Ready
SG2047
RA, SLE, IaA Neophropathy
TNFa/BAFF/APRIL
Phase 2 in China
SG2048
Hypertriglyceridemia
APOC3 (SiRNA)
IND Ready
SG2049
Anticoagulation
Factor XI (SiRNA)
Phase 1 in China
Asset #
Therapeutic Area
Target
Stage of Developement
SG2022
Immunology
TSLP Nanobody inhale
Phase 1 in China
SG2023
Immunology
IL-4Rα Nanobody inhale
Phase 1 in China
SG2026
Oncology
GPRC5D binder
Preclinical
SG2037
Oncology/Immunology
CD20/CD3
Phase 1 in China
SG2040
Diabetes/Obesity
GLP1/GIP
Phase 1 in China
SG2041
Oncology/Immunology
CD38/CD3
Preclinical
SG2043
Oncology/Immunology
BCMA/CD3
Phase 1 in China
SG2044
Oncology/Immunology
CD19/CD3
Phase 1 in China
SG2045
Immunology
BCMA/CD19/CD3
Preclinical
SG2046
RA, Osteoporosis
TNFa/RANKL
IND Ready
SG2047
RA, SLE, IaA Neophropathy
TNFa/BAFF/APRIL
Phase 2 in China
SG2048
Hypertriglyceridemia
APOC3 (SiRNA)
IND Ready
SG2049
Anticoagulation
Factor XI (SiRNA)
Phase 1 in China
Asset #
Therapeutic Area
Target
Stage of Developement
SG2022
Immunology
TSLP Nanobody inhale
Phase 1 in China
SG2023
Immunology
IL-4Rα Nanobody inhale
Phase 1 in China
SG2026
Oncology
GPRC5D binder
Preclinical
SG2037
Oncology/Immunology
CD20/CD3
Phase 1 in China
SG2040
Diabetes/Obesity
GLP1/GIP
Phase 1 in China
SG2041
Oncology/Immunology
CD38/CD3
Preclinical
SG2043
Oncology/Immunology
BCMA/CD3
Phase 1 in China
SG2044
Oncology/Immunology
CD19/CD3
Phase 1 in China
SG2045
Immunology
BCMA/CD19/CD3
Preclinical
SG2046
RA, Osteoporosis
TNFa/RANKL
IND Ready
SG2047
RA, SLE, IgA Neophropathy
TNFa/BAFF/APRIL
Phase 2 in China
SG2048
Hypertriglyceridemia
APOC3 (SiRNA)
IND Ready
SG2049
Anticoagulation
Factor XI (SiRNA)
Phase 1 in China
ADC
ADC
Asset #
Therapeutic Area
Target
Stage of Developement
SG5002
Oncology
Cldn18.2
Preclinical
Asset #
Therapeutic Area
Target
Stage of Developement
SG5002
Oncology
Cldn18.2
Preclinical
Asset #
Therapeutic Area
Target
Stage of Developement
SG5002
Oncology
Cldn18.2
Preclinical
Cell Therapy
Cell Therapy
Asset #
Therapeutic Area
Target
Stage of Developement
SG6001
Oncology
GBM
IIT
SG6002
Neuro
Parkinson's
Phase 1 in USA/China
Asset #
Therapeutic Area
Target
Stage of Developement
SG6001
Oncology
GBM
IIT
SG6002
Neuro
Parkinson's
Phase 1 in USA/China
Asset #
Therapeutic Area
Target
Stage of Developement
SG6001
Oncology
GBM
IIT
SG6002
Neuro
Parkinson's
Phase 1 in USA/China
Legal
© 2025 by Conexus Bio.
Legal
© 2025 by Conexus Bio.
Legal
© 2025 by Conexus Bio.